期刊
DRUG DELIVERY
卷 22, 期 7, 页码 903-910出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/10717544.2013.860501
关键词
Bioavailability; brain distribution; intranasal gels; pharmacokinetic studies; rasagiline mesylate
Intranasal thermosensitive gel for rasagiline mesylate (RM) was developed for effective treatment of Parkinson's disease. Intranasal gels were prepared by combination of poloxamer 407 and poloxamer 188 (1:1) with mucoadhesive polymers (carbopol 934P and chitosan). The formulations were evaluated for sol-gel transition temperature, in-vitro drug release and in-vivo mucociliary transit time. Further, optimal intranasal gel formulations were tested for in-vivo pharmacokinetic behavior, nasal toxicity studies and brain uptake studies. It was found that optimal formulations had acceptable gelation temperature (28-33 degrees C) and adequate in-vitro drug release profile. Pharmacokinetic study in rabbits showed significant (p<0.05) improvement in bioavailability (four- to six-folds) of the drug from intranasal gels than oral solution. Chronic exposure studies in Wistar rats showed that these intranasal gels were non-irritant and non-toxic to rat nasal mucosa. Estimation of RM in rat brain tissue showed significant (p<0.01) improvement in uptake of RM form intranasal gel formulations than nasal solution.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据